References
Freestone B, Lip GYH . Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J (eds). Cardiac Arrhythmias: A Clinical Approach. Mosby: Edinburgh, 2003, pp 3–24.
Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG . Hypertensive heart disease. A complex syndrome or a hypertensive ’cardiomyopathy‘? Eur Heart J 2000; 21 (20): 1653–1665.
Gage BF et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.
Bautista LE . Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223–230.
Schram MT et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429–437.
Bautista LE, Vera LM, Arenas IA, Gamarra G . Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19: 149–154.
Lip GYH . Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14: 687–690.
Lip GYH . Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313–1314.
Freestone B, Beevers DG, Lip GY . The renin–angiotensin–aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004; 18: 461–465.
Choudhury A, Varughese G, Lip GYH . Targeting the Renin Angiotensin Aldosterone System in Atrial Fibrillation: a shift from electrical to structural therapy? Exp Opin Pharmacother 2005 (in press).
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA . Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954–1968.
Hertervig EJ et al. Evidence for electrical remodelling of the atrial myocardium in patients with atrial fibrillation. A study using the monophasic action potential recording technique. Clin Physiol Funct Imaging 2002; 22: 8–12.
Lau CP, Tse HF . Electrical remodelling of chronic atrial fibrillation. Clin Exp Pharmacol Physiol 1997; 24: 982–983.
Boldt A et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400–405.
Kostin S et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54: 361–379.
Schotten U et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001; 103: 691–698.
Shi Y et al. Remodelling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001; 52: 217–225.
Kaschina E, Unger T . Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure 2003; 12: 70–88.
Rogg H et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996; 17: 1112–1120.
Matsubara H . Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182–1191.
Goette A et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678–2681.
Boldt A et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 1785–1792.
Goette A et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669–1677.
Yano M et al. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 1998; 83: 752–760.
Cardin S et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315–325.
Engelmann MD, Svendsen JH . Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J [Epub ahead of print; doi:10.1093/eurheartj/chi350].
Das UN . Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155–RA162.
Tsai CT et al. Renin–angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640–1646.
Ogimoto A et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47: 184–189.
Gensini F et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26: 295–298.
Brown NJ, Vaughan DE . Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419–429.
Healey JS et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832–1839.
Swedberg K et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from the CHARM study (abstr). J Am Coll Cardiol 2004; 23 (Suppl A): 222A.
Maggioni AP et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548–557.
Wachtell K et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–719.
Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension (STOP)-2 study. Lancet 1999; 354: 1751–1756.
Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
Vermes E et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–2931.
Pedersen OD, Bagger H, Kober L, Torp-Pedersen C . The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20: 748–754.
Madrid AH et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331–336.
Ueng KC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090–2098.
Gavras I, Gavras H . The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 2000; 13: 512–517.
van Eickels M et al. Angiotensin-converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn-Schmiedeberg's Arch Pharmacol 1999; 359: 394–399.
Li D et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608–2614.
Nakashima H et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612–2617.
Kumagai K et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197–2204.
Kothari SA, Le MK, Gandhi PJ . Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis 2003; 15: 217–225.
Willaims B et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–185.
He FJ, MacGregor GA . Cost of poor blood pressure control in the UK: 62 000 unnecessary deaths per year. J Hum Hypertens 2003; 17: 455–457.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boos, C., Lip, G. Targeting the renin–angiotensin–aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 19, 855–859 (2005). https://doi.org/10.1038/sj.jhh.1001933
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001933
- Springer Nature Limited
This article is cited by
-
During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate?
Journal of Human Hypertension (2013)
-
Predictors of atrial fibrillation occurrence after coronary artery bypass graft surgery
General Thoracic and Cardiovascular Surgery (2011)
-
Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery
BMC Cardiovascular Disorders (2010)
-
The 2007 revised ESC/ESH Guidelines in the management of hypertension: clarifying individual patient care
Journal of Human Hypertension (2007)
-
Blood pressure measurement in atrial fibrillation: goodbye mercury?
Journal of Human Hypertension (2006)